Furthermore, EZH2 inhibition can increase the cytotoxicity of human effector T cells in vitro and improve the efficacy of anti-CTLA-4 therapy in murine bladder cancer and melanoma as anti-CTLA-4 increases the expression of EZH2 in peripheral T cells [94]. Here, CTLA4 is linked to urinary bladder carcinoma.